Skip to Main Content
Contribute Try STAT+ Today

Pharmalittle: SEC probes Cassava over Alzheimer’s drug results; Teva takes pharma in a new direction with a bond sale

The SEC is investigating claims Cassava Sciences manipulated research results of its experimental Alzheimer’s drug.

Outdated rule increases Medicare’s costs for generic drugs by $26 billion a year

Lowering what Medicare pays for dispensing generic drugs along with administration's proposal to limit price increases on brand-name drugs could generate enough savings to pay for expanding Medicare benefits without new taxes.

Pharmalittle: Sanofi will acquire Kadmon Pharma for $1.9 billion; Theranos founder Elizabeth Holmes goes on trial

Sanofi said Wednesday it will acquire Kadmon Pharmaceuticals for $1.9 billion, bolstering its transplant medicines business.

Biden wants to bolster the pharma supply chain. A major generic plant closing may make that harder

“We view this plant as a critical resource to ensure generic access for our patients,” said Reshma Ramachandran, co-chair of the drug affordability action team at Doctors For America.

Pharmalittle: ICER medical experts find no benefit for Aduhelm; FDA panel votes down Fibrogen’s anemia drug

An FDA expert panel concluded that risks of blood clots and other safety concerns tied to Fibrogen’s anemia pill were too high to support the drug’s approval.

Faster approval of complex generics is central to affordable, equitable care

For millions of American families, access to medicines such as quick-relief asthma inhalers or epinephrine auto-injectors can be a life-or-death matter.

Reining in drug patents isn’t a silver bullet against high drug prices

Changing patent policy is a blunt instrument that is likely to miss the target of lowering drug prices and is an entirely roundabout way to get at the problem.

Pharmalittle: GSK to partner with CureVac on Covid-19 vaccine; Jazz to buy GW Pharma in $7.2 billion deal

Jazz Pharmaceuticals agreed to buy GW Pharmaceuticals to expand its neuroscience business by adding cannabis-based epilepsy treatment to its suite of drugs.

Comparing the Covid-19 vaccines developed by Pfizer, Moderna, and Johnson & Johnson

How three Covid-19 vaccines — from Pfizer, Moderna, and J&J — stack up against one another.

Covid-19 vaccine basics: Why the rollout is so slow, who can get doses, and what about side effects

Covid-19 vaccine basics: Why the rollout is so slow, when it will pick up, and who can get it.

CDC reports rare allergic reactions to Moderna’s Covid-19 vaccine

The CDC reported Friday that Moderna's Covid-19 vaccine appears to induce rare anaphylactic reactions in a small number of people.

Pharmalittle: U.S. health officials seek more use of Covid-19 antibody drugs; Pfizer to reduce vaccine supplies to Europe

U.S. officials are pleading for more use of Covid-19 antibody therapies from Eli Lilly and Regeneron Pharmaceuticals that have been plagued by logistical issues, lack of efficacy data, and insufficient reimbursement.

CDC reports more allergic reactions to Covid-19 vaccines, but cases remain few

Twenty-nine people in the U.S. have developed anaphylaxis after being vaccinated against Covid-19, but health officials say the vaccines remain very safe overall.

Messonnier: The slow vaccine rollout should speed up ‘pretty massively’ in coming weeks

Top CDC official Nancy Messonnier acknowledged that the administration’s vaccine rollout has been rocky so far. But in a conversation with STAT, she predicted that it’ll speed up soon.

The curse of the incidental illness: Seen as side effects to Covid vaccinations, ailments may have little to do with them

Quickly distinguishing any signal from an abundance of noise will be critical to ease the alarm of a public already skittish about vaccines developed at “warp speed,” experts warned.

CDC advisory panel unanimously recommends use of Moderna Covid-19 vaccine

An expert panel that advises the CDC voted unanimously on Saturday to recommend use of Moderna’s Covid-19 vaccine.

A guide to who can safely get the Pfizer/BioNTech Covid-19 vaccine

With the first doses of Covid-19 vaccine being administered across the United States, questions abound about who can safely get them. Here are some answers.

Moral foundations theory can help rehabilitate pharma’s image

The focus of this rehabilitation effort should focus on how the industry helps care for people and the efforts it is taking to protect people from harm. That is, after all, what the pharmaceutical industry does.

First-of-its-kind examination shows how widely pharma showers campaign cash at the state level

In California, 86% of state lawmakers took campaign contributions from pharma. In Illinois, it’s 79%. Find figures for every state legislature in a first-of-its-kind STAT analysis of the drug industry’s political donations.

How Trump could use a rare regulatory maneuver to lower drug prices before Election Day, and how it could backfire 

There’s a way for Trump to pull off a major, last-minute drug pricing change before Election Day — and pharma lobbyists are worried he just might. 

Trump campaign’s Facebook ad blitz casts Biden as pharma’s preferred candidate

In Facebook and Instagram ads launched on Sunday, Trump touts a plan to lower prescription drug prices and casts his Democratic opponent as the drug industry’s preferred candidate.

Trump administration unveils executive orders to curb drug prices — but they come with caveats

The Trump administration unveiled four executive orders on Friday aimed at bringing down pharmaceutical prices — a last-ditch effort to cut drug costs before the November election.

Startup developing an inhaler for seizures is acquired by UCB

A startup conceived to improve emergency treatment for epileptic seizures based on a father’s fears for his son’s safety has been sold to a large biopharma company also making a rescue therapy for the dangerous attacks.

Phlow CEO speaks out on criticism of his record, plans for a drug ingredient stockpile, and a huge government contract

STAT spoke with Phlow CEO Eric Edwards about the criticism over his track record, Phlow's plan to create a national drug ingredient stockpile, and the huge government contract the company recently scored.

CEO tapped by Trump to make generic drugs during pandemic has a dicey track record

Experts said the government's decision to award a major generic drug manufacturing contract to Phlow — a company led by Kaleo co-founder Eric Edwards — raises eyebrows.

Pharmalittle: Scientists say coronavirus is not mutating significantly; WHO is asked to pool Covid-19 patent rights

The Indian government banned exports of hydroxychloroquine, which President Trump touted as a possible weapon in the fight against Covid-19.

Generic ‘identity’ gets lost when companies juggle both generic and brand drugs

Playing both sides of the market may reduce the incentive for generic companies that also own branded drugs to fight as hard as possible to win patent challenges and other cases.

Pharmalittle: Canada may change new rules for drug prices; Trump frustrated over drug pricing

President Trump is campaigning for re-election in 2020 by saying he has made great progress in reducing drug prices, but the issue has been a source of frustration for him recently.

Pharmalittle: Two more Alzheimer’s drugs fail in studies; how Democratic candidates differ on lowering drug costs

Every Democratic presidential candidate agrees the federal government should take a far more aggressive approach to lowering drug costs — but there are quite a few differences.